Upregulation of Nm23, a Metastasis Suppressor Gene, in Human Prostate Adenocarcinoma (PC-3) Cell Line Treated with Imatinib

Document Type : Original Article (s)

Authors

1 PhD Student, Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.

2 Assistant Professor, Department of Radiopharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

3 Assistant Professor, Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran

4 Associate Professor, Biotechnology Research Center, Pasteur Institute of Iran AND Medical Biotechnology Group, Venom and Toxin Lab, Tehran, Iran

Abstract

Background: Prostate cancer is one of the most common cancers diagnosed in developed countries. Many studies have confirmed that the nm23 gene suppresses metastasis in different types of cancers. The effects of, imatinib as the first member of tyrosine kinases inhibitors, were showed in research and treatment of solid tumors. The aim of the current study was to investigate the effect of imatinib on cell viability and suppressor metastasis nm23 gene expression in prostate cancer cell line.Methods: In this study, prostate cancer (PC-3) human cell line was treated with various concentrations of imatinib for 48 hours. Cell viability was assessed using MTT assay [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] and the half maximal inhibitory concentration (IC50) value was determined. We extracted RNA molecules via using RNX solution, after which cDNA was synthesized. The precise primers for the nm23 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) genes were designed via specific software. Then, the quantity of nm23 compared to GAPDH gene (reference gene) was analyzed using real-time polymerase chain reaction (PCR) method.Findings: Imatinib exerted an inhibitory effect on the viability of metastatic PC-3 cells. The calculated nm23/GAPDH gene expression ratio was 1.62 ± 0.02 (P < 0.01) in 21/33 mM concentration of imatinib at 48 hours.Conclusion: The results of this study showed that imatinib can inhibit metastasis via upregulating nm23 gene expression in prostate cancer adenocarcinoma PC-3 cell line.

Keywords

References

  1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64(1): 9-29.
  2. Noori Daloii MR, brahimzadeh Vesal E. Molecular genetic, diagnosis, prevention and gene therapy in prostatic cancer: review article. Tehran Univ Med J 2009; 67(1): 1-14. [In Persian].
  3. Nazir S, Hussain T, Ayub A, Rashid U, MacRobert AJ. Nanomaterials in combating cancer: therapeutic applications and developments. Nanomedicine 2014; 10(1): 19-34.
  4. Gur S, Sikka SC, Abdel-Mageed AB, Abd Elmageed ZY, Rezk B, Pankey E, et al. Imatinib mesylate (Gleevec) induces human corpus cavernosum relaxation by inhibiting receptor tyrosine kinases (RTKs): identification of new RTK targets. Urology 2013; 82(3): 745-6.
  5. Tornillo L. Biology of gastrointestinal stromal tumour and mechanisms of imatinib resistance. Diagnostic Histopathology 2013; 19(6): 203-10.
  6. Pytel D, Sliwinski T, Poplawski T, Ferriola D, Majsterek I. Tyrosine kinase blockers: new hope for successful cancer therapy. Anticancer Agents Med Chem 2009; 9(1): 66-76.
  7. Weigel MT, Meinhold-Heerlein I, Bauerschlag DO, Schem C, Bauer M, Jonat W, et al. Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling. Cancer Lett 2009; 273(1): 70-9.
  8. Iiizumi M, Liu W, Pai SK, Furuta E, Watabe K. Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy. Biochim Biophys Acta 2008; 1786(2): 87-104.
  9. Prabhu VV, Siddikuzzaman, Grace VM, Guruvayoorappan C. Targeting tumor metastasis by regulating Nm23 gene expression. Asian Pac J Cancer Prev 2012; 13(8): 3539-48.
  10. Haeno H, Michor F. The evolution of tumor metastases during clonal expansion. J Theor Biol 2010; 263(1): 30-44.
  11. Fournier HN, Albiges-Rizo C, Block MR. New insights into Nm23 control of cell adhesion and migration. J Bioenerg Biomembr 2003; 35(1): 81-7.
  12. Royds JA, Silcocks PB, Rees RC, Stephenson TJ. Nm23 protein expression in thyroid neoplasms. Pathologica 1994; 86(3): 240-3.
  13. Bevilacqua G, Sobel ME, Liotta LA, Steeg PS. Association of low nm23 RNA levels in human primary infiltrating ductal breast carcinomas with lymph node involvement and other histopathological indicators of high metastatic potential. Cancer Res 1989; 49(18): 5185-90.
  14. Caligo MA, Grammatico P, Cipollini G, Varesco L, Del PG, Bevilacqua G. A low NM23.H1 gene expression identifying high malignancy human melanomas. Melanoma Res 1994; 4(3): 179-84.
  15. Boix L, Bruix J, Campo E, Sole M, Castells A, Fuster J, et al. nm23-H1 expression and disease recurrence after surgical resection of small hepatocellular carcinoma. Gastroenterology 1994; 107(2): 486-91.
  16. Kapitanovic S, Spaventi R, Vujsic S, Petrovic Z, Kurjak A, Pavelic ZP, et al. nm23-H1 gene expression in ovarian tumors--a potential tumor marker. Anticancer Res 1995; 15(2): 587-90.
  17. Wakimoto N, Yokoyama A, Okabe-Kado J, Nagata N, Motoyoshi K, Honma Y. Combined analysis of differentiation inhibitory factor nm23-H1 and nm23-H2 as prognostic factors in acute myeloid leukaemia. Br J Cancer 1998; 77(12): 2298-303.
  18. Igawa M, Urakami S, Shiina H, Ishibe T, Usui T, Chodak GW. Association of nm23 protein levels in human prostates with proliferating cell nuclear antigen expression at autopsy. Eur Urol 1996; 30(3): 383-7.
  19. Roskoski R, Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res 2014; 79: 34-74.
  20. Rocha A, Azevedo I, Soares R. Progesterone sensitizes breast cancer MCF7 cells to imatinib inhibitory effects. J Cell Biochem 2008; 103(2): 607-14.
  21. Popow-Wozniak A, Wozniakowska A, Kaczmarek L, Malicka-Blaszkiewicz M, Nowak D. Apoptotic effect of imatinib on human colon adenocarcinoma cells: influence on actin cytoskeleton organization and cell migration. Eur J Pharmacol 2011; 667(1-3): 66-73.
  22. Weigel MT, Dahmke L, Schem C, Bauerschlag DO, Weber K, Niehoff P, et al. In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells. BMC Cancer 2010; 10: 412.
  23. Basciani S, Brama M, Mariani S, De LG, Arizzi M, Vesci L, et al. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity. Cancer Res 2005; 65(5): 1897-903.
  24. Reynoso D, Nolden LK, Yang D, Dumont SN, Conley AP, Dumont AG, et al. Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells. Mol Oncol 2011; 5(1): 93-104.
  25. Abouantoun TJ, MacDonald TJ. Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor. Mol Cancer Ther 2009; 8(5): 1137-47.
  26. Biswas SK, Zhao Y, Sandirasegarane L. Imatinib induces apoptosis by inhibiting. Mol Vis 2009; 15: 1599-610.
  27. Patel BB, He YA, Li XM, Frolov A, Vanderveer L, Slater C, et al. Molecular mechanisms of action of imatinib mesylate in human ovarian cancer: a proteomic analysis. Cancer Genomics Proteomics 2008; 5(3-4): 137-49.
Journal of Isfahan Medical School
Volume 32, Issue 309 - Serial Number 309
September and October 2015
Pages 1907-1917

Files

History

  • Receive Date: 28 November 2014
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics